For many years, people newly diagnosed with Parkinsonโs disease (PD) were often started on a dopamine agonist rather than levodopa. Today, that approach has changed. For many patientsโparticularly adults over age 60โcarbidopa/levodopa (Sinemet) is now the preferred first treatment when Parkinsonโs symptoms begin to interfere with daily life.
PD causes symptoms such as slowness, stiffness and tremor because the brain gradually loses cells that produce dopamine. Levodopa is converted into dopamine in the brain and is generally the most effective medication for improving these movement symptoms.
In the past, doctors sometimes delayed levodopa because of concerns that long-term treatment would lead to dyskinesias, or involuntary extra movements, and fluctuations in how well the medication worked. There was also a belief that starting levodopa early might cause it to โstop workingโ sooner.
Because of these concerns, younger patients in particular were often started on dopamine agonists such as Mirapex, Requip, or Neupro. These medications stimulate dopamine receptors directly and can improve PD symptoms without using levodopa.
We now know that levodopa does not simply โwear outโ because someone starts taking it early. Motor fluctuations and dyskinesias appear to be strongly related to the progression of PD itself, as well as the dose and duration of levodopa exposure. Importantly, levodopa generally provides better improvement in movement symptoms than dopamine agonists.
Dopamine agonist are now known to have side effects, such as sleepiness, dizziness, leg swelling, hallucinations, confusion and impulse control disorders.
Currently, carbidopa/levodopa is the preferred initial medication when movement symptoms require treatment. Dopamine agonists still have an important role, but their potential side effects are considered more carefully than they were in the past.
The BeCare Neuro and Parkinson’s apps can help by tracking neurological function and mental health issues. Become a driver in your own neurologic care with BeCare.
